OMERHealthcare · BiotechnologyThe 3 Wall Street analysts covering Omeros Corp. hold a median 12-month price target of $28 — +43.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 8 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Omeros Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (98): Analysts have, on balance, been raising their forecasts.
Volatility (31): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on OMER, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +43.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Sept 2026 | Cantor Fitzgerald | Upgrade | Overweight | $22 |
| 26 June 2026 | HC Wainwright & Co. | Maintains | Buy | $40 → $33 |
| 26 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 27 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 8 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 8 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 1 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 14 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 16 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 15 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 15 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Oct 2025 | Needham | Reiterates | Hold | — |
| 15 Oct 2025 | WBB Securities | Reiterates | Strong Buy | — |
| 3 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 15 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 15 Aug 2025 | Needham | Reiterates | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OMER appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Omeros Corp. returned +335.5% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 45% of US stocks
Cheaper than 7% of US stocks
Cheaper than 99% of US stocks
Cheaper than 90% of US stocks
Higher than 96% of US stocks
Higher than 99% of US stocks
Higher than 46% of US stocks
Higher than 99% of US stocks
Higher than 49% of US stocks
Higher than 20% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Omeros Corp. has a market value of $1.3B and an enterprise value of $1.5B.
Revenue in the twelve months to 30 June 2026: $38.4M. The latest quarter grew 188.4% year on year.
Net income over the same four quarters: $124.8M, a 324.9% net margin.
Diluted earnings per share, trailing twelve months: $1.28.
Free cash flow in the twelve months to 30 June 2026: −$68.7M.
Omeros Corp. spent $9.9M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 15.2×; forward P/E: 15.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Omeros Corp. employs 175 people — $220K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Omeros Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Cantor Fitzgerald upgraded Omeros Corp, citing a better-than-expected launch of its transplant drug Yartemlea. The analyst suggested the drug could be bigger than previously anticipated.
Why it matters — The upgrade and favorable launch assessment point to stronger commercial prospects for Omeros's transplant drug Yartemlea, a key product for the company.
Zacks Investment Research published an article asking whether Omeros (OMER) qualifies as a top stock pick for momentum investors. The piece frames the stock as potentially strong on momentum criteria.
Why it matters — A OMER watcher would care because it signals renewed analyst attention on the stock's momentum characteristics, which can influence investor perception.
Omeros Corporation's 50-day simple moving average crossed above its 200-day simple moving average, a technical pattern known as a "golden cross," which the company reached at a key level of support. The article highlights this as an interesting development from a technical perspective.
Why it matters — OMER watchers would care because the golden cross is a widely followed technical signal that indicates a potential shift in the stock's momentum trend.
Omeros stock surged to a five-year high Thursday after the company reported strong second-quarter results for its new treatment for transplant complications.
Why it matters — A OMER watcher would care because the company's stock reached a five-year high on the back of strong quarterly results for its new transplant-complication treatment, signalling notable commercial progress.
Seeking Alpha published the transcript of Omeros Corporation's second-quarter 2026 earnings call. The transcript covers the company's Q2 2026 earnings discussion.
Why it matters — OMER watchers would care because the earnings call transcript provides insight into the company's quarterly financial performance and management commentary.
The 3 Wall Street analysts covering Omeros Corp. have a median 12-month price target of $28, with estimates ranging from $22 to $33. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Omeros Corp., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Omeros Corp. 93 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Omeros Corp. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (98 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +43.8% from the last close, and Ticker Nerd's factor model ranks Omeros Corp. 93 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Omeros Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OMER are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $33 over the next 12 months.
Omeros Corp. returned +335.5% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Omeros Corp. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics.
The most recent item we track (Benzinga, 22 Sept 2026): "Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst". Cantor Fitzgerald upgraded Omeros Corp, citing a better-than-expected launch of its transplant drug Yartemlea. The analyst suggested the drug could be bigger than previously anticipated.
Omeros Corp. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics. The company concentrates on immunologic and complement-mediated diseases, along with selected orphan and rare indications affecting inflammation, coagulopathies, and central nervous system disorders. Its portfolio includes commercial and development-stage programs designed to address unmet medical needs across hematology, nephrology, immunology, oncology, and addiction-related conditions. Omeros also works on targeted therapeutics that modulate the complement pathway, a key part of the immune system involved in several serious diseases. Headquartered in Seattle, Washington, Omeros Corp. plays a specialized role in the biotechnology market by advancing differentiated therapies from research through commercialization.
CEO Dr. Gregory A. Demopulos M.D. · 175 employees · United States · https://www.omeros.com
